New Eliquis Information Revealed From Recent Study
Allegations which our firm made in the first Eliquis suit have been explored in an investigative newspaper report appearing in the Milwaukee Journal Sentinel. In the suit we started, for the death of a man who had bleeding in his brain while on Eliquis, we pleaded that the makers of this blood thinner had concealed from prescribers and users that data was missing from reports on clinical investigations before the drug was marketed in 2013.
The law suit was Herschell v. Bristol-Myers Squibb et al., Southern District of New York, Docket No.: 1:15-cv-04620 (2015). The newspaper article is by Fauber on Aug. 2, 2015, and can be found online on "The Slippery Slope" website.
In the clinical trials performed by the Eliquis makers, in order to prove safety and efficacy, data on more than 300 subjects who got Eliquis was missing. If there were some deaths among those unaccounted for-due to bleeding as in the Herschell case or other causes-that would have statistically made it hard for the sellers to claim that there were less bleeds and deaths with this new blood thinner compared to the traditional product used-Coumadin (known generically as warfarin).
The absence of this important data was noted by an FDA medical examiner, Thomas Marcinak, M.D., as we pleaded in the suit. He felt that that prescribing physicians should be informed of this, especially since the p value (a statistical probability test) was marginal. However, as Fauber explained in his article, the FDA bosses overruled him. Fauber then spoke with a Yale expert on the design of clinical studies, who said that Marcinak was making a valid point.
In another piece posted on "The Slippery Slope" website, also dated Aug. 2, 2015, Fauber added other criticisms of Eliquis as well as Xarelto and Pradaxa, other new blood thinners. At least 8000 deaths had been reported in users of these drugs, whereas only 700 have been reported on warfarin in the same time period. This article can also be found on the site "MedPage Today."
The Milwaukee reporter, Fauber, quoted a well-known cardiologist, Rita Redberg, as saying that she was not prescribing these new anticoagulants-known collectively as NOACs-at least until more experience had passed. She stated that Eliquis (known as apixaban generically) and the other NOACs might be causing more harm than good. Eliquis is marketed for clot prevent in atrial fibrillation and also DVT and PE prevention.
If you or someone you or someone you know has been harmed by the drug Eliquis, contact ustoday online or by telephone at (888) 260-0473 to speak with an experienced New York dangerous drugs liability law firm. Our firm will handle you case from start to finish.